A Phase 2 interventional study of JDB0131 100mg and JDB0131 200mg in Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis and Rifampicin-resistant Tuberculosis, sponsored by WestVac Biopharma Co., Ltd.. Recruiting at 7 sites in China. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by WestVac Biopharma Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Tuberculosis with a site in China — 22 open to participants now, 25 under way, 5 of them phase 3. Tuberculosis · China.
Among the 62 studies in Tuberculosis with a site in China, this one is the 39th largest by planned enrollment of the 47 interventional ones that give a count, is one of 8 that started in 2025, is one of 10 in phase 2, reaches primary completion later than 7 of the 24 other live ones, and was the 54th registered.
1,173 studies on the registry are indexed under Tuberculosis; 177 are open to participants now.
Browse Tuberculosis studies →22 of the 62 studies in Tuberculosis with a site in China are open now. Recruiting first, the newest first:
Huashan Hospital · Sites in China
Ages 3 mo–18 yrs
Beijing Chest Hospital, Capital Medical University · Sites in China
Ages 18–100 · Healthy volunteers
Huashan Hospital · Sites in China
Ages 14–80
Xuelin Yang · Sites in China
Ages 15+ · Healthy volunteers
Chengdu CoenBiotech Co., Ltd · Sites in China
Ages 3+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 112 Tuberculosis studies recruiting now, 65 (58%) set no upper age limit and 37 (33%) stop at 75 or younger; 49 take children under 18; 31 take healthy volunteers.
This study: 14 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 13 · Phase 3 10 · Phase 4 6
First in 2004; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 150 across 822 interventional studies indexed under Tuberculosis.
Median enrollment 241 across the 47 interventional studies, 500 across the 15 observational. Of the 26 that completed or were terminated, 3 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 62 have an industry lead sponsor. The 10 most frequent:
WestVac Biopharma Co., Ltd. is the lead sponsor of 14 studies on the registry; 6 are open to participants now.
WestVac Biopharma Co., Ltd. has 1 study filed under Tuberculosis — fewer than ten, so there is no comparison to draw.
4 of the studies in Tuberculosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07575061Beijing Chest Hospital, Capital Medical UniversityA 15-year Cohort Study on Risk Factors of Mortality in Patients With Intestinal Tuberculosis | 2026-12-01 |
| NCT07459569China-Japan Friendship HospitalDiagnostic Performance and Safety of Endobronchial Ultrasound-guided Transbronchial Mediastinal Cryobiopsy in Diagnosing Tuberculous Mediastinal Lymphadenitis: a Randomised Controlled Trial | 2027-05 |
| NCT06153069Huashan HospitalAsymptomatic TB With Innovative Modified Short-course Regimens | 2027-11 |
| NCT07893444Huashan HospitalBRIGHT-Child TB: Short-Course Treatment for Non-Severe Pulmonary Tuberculosis in Children | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 62 studies in Tuberculosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, open-label, active-controlled clinical study designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of different doses of JDB0131 benzenesulfonate tablets compared with delamanid in combination with bedaquiline, linezolid, levofloxacin (moxifloxacin)/clofazimine, etc. in the treatment of patients with drug-resistant (including rifampicin-resistant) tuberculosis for 8 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Anyone with any of the following cardiovascular diseases or other conditions within 6 months before enrollment:
Laboratory tests show any of the following:
The following abnormalities were found in the (ECG):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bedaquiline (B) and JDB0131 (J) and Linezolid (L) and Levofloxacin (Lfx) or (Moxifloxacin (M)) / Clofazimine (C) Patients will take medications for 8 consecutive weeks. Patients will be randomized based on fluoroquinolone resistance. If fluoroquinolone-susceptible, patients in group A will receive Levofloxacin (Lfx) or Moxifloxacin (M). If fluoroquinolone-resistant, patients in group A will receive Clofazimine (C).
Drug: JDB0131 100mg
Bedaquiline (B) and JDB0131 (J) and Linezolid (L) and Levofloxacin (Lfx) or (Moxifloxacin (M)) / Clofazimine (C). Patients will take medications for 8 consecutive weeks. Patients will be randomized based on fluoroquinolone resistance. If fluoroquinolone-susceptible, patients in group A will receive Levofloxacin (Lfx) or Moxifloxacin (M). If fluoroquinolone-resistant, patients in group A will receive Clofazimine (C).
Drug: JDB0131 200mg
Bedaquiline (B) and Delamanid (D) and Linezolid (L) and Levofloxacin (Lfx) / Clofazimine (C). Patients will take medications for 8 consecutive weeks. Patients will be randomized based on fluoroquinolone resistance. If fluoroquinolone-susceptible, patients in group C will receive Levofloxacin (Lfx). If fluoroquinolone-resistant, patients in group C will receive Clofazimine (C).
Drug: Delamanid (D)
Bedaquiline (B): For the first 2 weeks, 400 mg qd; then adjust to 200 mg tiw. JDB0131 (J): 100 mg bid. Linezolid (L): 600 mg qd. Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd. Moxifloxacin (M): 400 mg qd. Clofazimine (C): 100 mg qd.
Bedaquiline (B): For the first 2 weeks, 400 mg qd; then adjust to 200 mg tiw. JDB0131 (J): 200 mg bid. Linezolid (L): 600 mg qd. Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd. Moxifloxacin (M): 400 mg qd. Clofazimine (C): 100 mg qd.
Bedaquiline (B): For the first 2 weeks, 400 mg qd; then adjust to 200 mg tiw. Delamanid (D): 100 mg bid. Linezolid (L): 600 mg qd. Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd. Moxifloxacin (M): 400 mg qd. Clofazimine (C): 100 mg qd.
Percentage of Patients with Sputum Culture Conversion (SCC)
SCC was defined as a patient without SCC at baseline who subsequently met the definition of SCC. A patient was classified as having achieved SCC if he/she achieved 2 consecutive sputum cultures negative for growth of mycobacterium tuberculosis (MTB) at least 7 days apart and had no further sputum cultures that were positive for growth within the specified time frame. Patients who have sputum cultures that were positive during treatment but only converted to negative at the end of treatment were also counted as negative.
Time frame: During the 8-week treatment period and after treatment
Time to Sputum Culture Conversion (SCC)
SCC was defined as a patient without SCC at baseline who subsequently met the definition of SCC. A patient was classified as having achieved SCC if he/she achieved 2 consecutive sputum cultures negative for growth of mycobacterium tuberculosis (MTB) at least 7 days apart and had no further sputum cultures that were positive for growth within the specified time frame. Patients who have sputum cultures that were positive during treatment but only converted to negative at the end of treatment were also counted as negative. Time to SCC was defined as the earliest time of two consecutive sputum cultures negative for growth, that is, the time (specimen collection time) of the first sputum culture negative for growth among two consecutive sputum cultures negative for growth of mycobacterium tuberculosis (MTB) at least 7 days apart was taken as the negative conversion time, expressed in days.
Time frame: During the 8-week treatment period and after treatment
Time to positivity (TTP)
Time-to-positivity (TTP) is defined as the length of time from the beginning of culture incubation to the positive detection of mycobacterium tuberculosis growth.
Time frame: During the 8-week treatment period and after treatment
Number of Participants With Clinically Significant Abnormality in Vital Signs
Vital signs included body temperature (degree Celsius), heart rate \[beats/minute (bpm)\], breathe \[times/minute (tpm)\], systolic and diastolic blood pressure \[millimetre of mercury (mm Hg)\].
Time frame: During the 8-week treatment period
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Values
The clinically significant abnormal ECG values including ventricular rate outlier, PR outlier, QRS outlier, QT outlier and QTcF outlier.
Time frame: During the 8-week treatment period
Number of Participants With Clinical Significant Abnormality in Laboratory Test
Laboratory assessments included parameters for serum chemistry (Aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, lactate dehydrogenase, glutamyl transpeptidase, total bilirubin, direct bilirubin, sodium, potassium, chlorine, urea, creatinine), hematology (Red blood cell count, hemoglobin concentration, mean corpuscular volume, white blood cell count, platelet count, neutrophil count, lymphocyte count, monocyte count, eosinophil count, basophil count), urinalysis (Urine leukocytes, urine red blood cells, urine pH, urine specific gravity, urine protein, urine glucose, urine occult blood), stool routine (stool characteristics, stool color, fecal white blood cells, fecal red blood cells, fecal occult blood test) and other serum chemistry (specified in protocol).
Time frame: During the 8-week treatment period
Number of Patients With Adverse Events (AEs) and at least one Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a participant/clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with treatment. A TEAE is any new AE or worsening of an existing condition after initiation of study drug.
Time frame: During the 8-week treatment period
Number of Patients With Serious Adverse Events (SAEs)
An SAE is an AE that resulted in death, inpatient hospitalization/prolongation of existing hospitalization, persistent or significant disability or incapacity, life-threatening, a congenital anomaly/birth defect, or an important medical event.
Time frame: During the 8-week treatment period
Number of Participants With Any Concomitant Medication Usage
Concomitant medications are defined as medications that started on or after the first day of study treatment or were started prior to study treatment but were ongoing on the first day of study treatment.
Time frame: During the 8-week treatment period
Time to peak (Tmax)
Time frame: During the 8-week treatment period (specified in protocol)
Peak concentration (Cmax)
Time frame: During the 8-week treatment period (specified in protocol)
Area under the plasma concentration-time curve from the first medication to 12 hours (AUC0-12)
Time frame: During the 8-week treatment period (specified in protocol)
Time to peak at steady state (Tss,max)
Time frame: During the 8-week treatment period (specified in protocol)
Peak concentration at steady state (Css,max)
Time frame: During the 8-week treatment period (specified in protocol)
Trough concentration at steady state (Css,min)
Time frame: During the 8-week treatment period (specified in protocol)
Average steady-state plasma concentration (Css,avg)
Time frame: During the 8-week treatment period (specified in protocol)
Elimination half-life (t1/2,ss)
Time frame: During the 8-week treatment period (specified in protocol)
Area under the plasma concentration-time curve from the last dose to 12 hours (AUC0-12,ss)
Time frame: During the 8-week treatment period (specified in protocol)
Area under the plasma concentration-time curve from the last dose to the last measurable concentration time t (AUC0-t,ss)
Time frame: During the 8-week treatment period (specified in protocol)
Area under the plasma concentration-time curve from the last dose extrapolated to infinity (AUC0-∞,ss)
Time frame: During the 8-week treatment period (specified in protocol)
Apparent volume of distribution (Vd,ss/F)
Time frame: During the 8-week treatment period (specified in protocol)
Oral clearance (CLss/F)
Time frame: During the 8-week treatment period (specified in protocol)
Accumulation ratio: Rac(Cmax) = Cmax,ss on day 56 / Cmax on day 1
Time frame: During the 8-week treatment period (specified in protocol)
Rac (AUC) = AUC0-12,ss on day 56 / AUC0-12 on day 1
Time frame: During the 8-week treatment period (specified in protocol)
Fluctuation coefficient: fluctuation percentage at steady state = 100 * (Css,max - Css,min) / Css,avg
Time frame: During the 8-week treatment period (specified in protocol)
Started Sep 2025 (actual). Primary completion is estimated for Feb 2026, 5 months after the start.
Of 64 phase 2 interventional studies under Tuberculosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 36. This study's planned 5 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
WestVac Biopharma Co., Ltd.